Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DIATREME RESOURCES LIMITED Capital/Financing Update 2013

Aug 19, 2013

64787_rns_2013-08-19_c4b883df-579c-4eb1-837b-6ae12c860063.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [71 x 74] intentionally omitted <==

DIATREME RESOURCES LIMITED

ABN: 33 061 267 061

Postal Address: P.O Box 10288 Brisbane Adelaide Street QLD 4000 Registered Office: Level 2 87 Wickham Terrace Spring Hill QLD 4000 PH: +61 (0)7 3832 5666 FX: +61 (0)7 3832 5300 www.diatreme.com.au [email protected]

==> picture [39 x 40] intentionally omitted <==

ASX : DRX

Companies Announcement Office Australian Securities Exchange Level 4, 20 Bridge Street Sydney NSW 2000

20 August 2013

Information disclosed under ASX LR 3.10.5A and 7.1A.4(b)

Further to the ASX announcement and Appendix 3B lodged by Diatreme Resources Limited ( Diatreme ) on 20 August 2013 regarding completion of the remaining $0.4M of a previously disclosed $1.6M placement to sophisticated investors, Diatreme provides the following information under ASX Listing Rule 3.10.5A:

  • (a) A total of 20,000,000 shares were issued under the Placement pursuant to Listing Rule 7.1A (representing 3.28% of the post-placement capital). Diatreme’s capacity under Listing Rule 7.1 has been fully utilised.

The percentage of the post-placement capital held (in aggregate) is as follows:

  • pre-placement security holders who did not participate in the placement - 80.2%

  • pre-placement security holders who did participate in the placement – 19.8%

  • participants in the placement who were not previously security holders - 0%

  • (b) Diatreme considered the placement to existing sophisticated investors as the most efficient and expedient method for raising the funds required to achieve its stated objectives given the funding certainty. The Company also considered that there were significant benefits with these investors’ participation which will add considerable value to the Company’s strategic goals.

  • (c) The placement was not underwritten.

  • (d) A 6% commission was incurred by Diatreme in connection with the placement.

For further details, please contact:

Tuan Do Joint Company Secretary

ASX Release – 20 August 2013 (2)